Physiomics Share Discussion Threads

[the stigologist] 14/9/2018 00:00

Sell in May, go away
Come again St Leger's Day



I'm thinking we could be getting some moonshoots

[spacedust] 13/9/2018 20:35

5.5p tomorrow.

[davevt] 13/9/2018 15:22

Stig is trying his hardest once again.

500k is peanuts, from an existing company that was already spending hundreds of k.

All pharmas dealing with cancer drugs are MAJOR, it's not like some back street small time ones have the power to do so.

Glaxo have been getting back into oncology for the last two years, Google it.

End of the day, pre clinical trials are only worth 35k. It doesn't matter if the number 1 super duper pharma turns up, if they have one drug to trial this year, it's 35 grand.

[the stigologist] 13/9/2018 14:39

2016 :- Ex-Glaxo 'New Drug-Discovery Technology Platform' Division guy Dr Jim Millen alights upon sub £1m stock market tiddler Physiomics

2017 :- Signs the first mega money deal with Big Pharma co Merck

2018 :- January - 'pilot/trial with a MAJOR Pharma'
2018 :- Spring - Hire another data scientist to deal with more clients
2018 :- July - Glaxo announce getting back into Oncology (PYC speciality)
2018 :- Sept/Oct - ???

[the stigologist] 13/9/2018 14:35

Clever investors starting to spot the opportunity and join the dots

riddler
Posts: 82,067
Opinion: No Opinion
Price: 4.90
RE: All points to Glaxo imho

Today 13:34





riddler
Posts: 82,067
Premium Chat Member
Opinion: No Opinion
Price: 4.85
All points to Glaxo imho

Today 13:32

Look at background of CEO and also GSK new move back into Oncology

[spacedust] 13/9/2018 13:02

Apparently this share moonshots to 100p....what a load of tosh

[davevt] 13/9/2018 09:31

You definitely are impotent. Much like this share lol

[the stigologist] 13/9/2018 09:01

Gaps get filled

Nice juicy one up to 6p

[pwhite73] 13/9/2018 07:54

OfficerDigby

I'll dig it out later but the MM instigated the rise because there was interest in another Oxford biotech spin-off in the last two weeks. I'll get the name later.

must dash

[the stigologist] 12/9/2018 23:17

I am impotent.

[officerdigby] 12/9/2018 21:45

Rise might have been due to Stiggy, ramping s bit of interest on few BB's I wonder.

[bobdown2] 12/9/2018 21:11

Just tried the knife and fork test..gold3n cross looks good..

[spacedust] 12/9/2018 20:58

Can't see a single golden cross

[the stigologist] 12/9/2018 20:33

PYC

Golden Cross

[spacedust] 12/9/2018 19:05

When was the last time this moonshot to 100p???? All it's done is come down from 100p

[the stigologist] 12/9/2018 15:29

Zak Mir on PYC

[bobby.ifa] 12/9/2018 15:01

Retrace nearly complete, more Pi's spiked for a few more years then.

[rolaw1] 12/9/2018 14:40

Appreciate the replies guys - thank you

[davevt] 12/9/2018 14:28

Stig misses the fact it's taken so many many years for Merck to get to a mere 500k. Because you start with pre clinical trials at 35k each for each drug, test them which can take years, progress on to the next, progress to clinical trials which command more money, but takes years to get to this stage.

So no new company is going to rock up and pay 500k unless they have 15 brand new cancer drugs to try. Last time I looked even the big boys are lucky to get a new drug out every couple of years.

Also pyc is nothing like simulations plus. They are a drug design company, actually using virtual reality to design how drugs work.

Pyc only do dosage prediction...something all drug companies already do. It's a non essential service pyc are offering.

If you go through Stigs waffle you can see he has no idea what pyc actually does, as he keeps comparing it to companies who do completely different things, INCLUDING everything that pyc offers. That's why they are getting the business and pyc turns over less than your local shop.

[the stigologist] 12/9/2018 14:21

Independent Industry Market Research Analysts put Physiomics as a top vendor in this software category alongside $850m Certara and $400m Simulations Plus

[the stigologist] 12/9/2018 14:19

rolaw1

The chart speaks for itself.

If one global pharma is happy to spend £500k a year
and several other bios and big pharmas are trialling this stuff anybody with any intelligence can work it out

Comparitor companies like Simulations Plus on Nasdaq are valued at $400m odd on $20m annual revenue, so apply that 'rating' to Physiomics revenues.

£0.5m rev should = £10m Mkt Cap
£1.0m rev should = £20m Mkt Cap
£1.5m rev should = £30m Mkt Cap

i.e. Physiomics only need to sign 2 more Merck size deals and it should 10 bag

I have a track record on here of calling 10 baggers

Look at VRS board September 2017 (VRS was 12p) i called it as a 10 or 100 bagger. So far one year on it's been a 15 bagger.

[davevt] 12/9/2018 14:05

Why did Merck invest £500k?

Lol, maybe you don't realise they have already spend hundreds of k a year with pyc since 2012. This year it's more money because they are progressing to clinical trials from pre clinical.

Also, I'm pretty sure Merck spend more than 500k a year on window cleaners for their buildings, or free coffee for their 65,000 employees. 500k is so much like peanuts to them, that it's cheaper than buying actual peanuts.

[spacedust] 12/9/2018 13:46

Is this the end of the fun and games. I was hoping they take it up over 10p to entice more mugs in